Author

Anne-Florence Blandin

Dana-Farber/Boston Children's Cancer and Blood Disorders CenterORCID 0000-0002-9000-910XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Advaita Chakraborty· 1 shared Alejandra E. Aguilar-QuinteroiD· 1 shared Brian D. CromptoniD· 1 shared Brigit McDannell· 1 shared Caleb HeaslipiD· 1 shared David Stephen ShulmaniD· 1 shared Helen F. Gloege· 1 shared Kelly S. KlegaiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Advaita Chakraborty

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma.

Helen F. Gloege, Maria Ana Isabel C. De Los Santos, Advaita Chakraborty, Madhav Chadha, Alejandra E. Aguilar-Quintero, Min Shen, Caleb Heaslip, Sarah Finstuen-Magro, Brigit McDannell, Mohammad Tanhaemami, Stephanie C. Meyer, Kelly S. Klega, Yaqin Zhang, David Stephen Shulman, Steven G. DuBois, , Brian D. Crompton

This paper identifies a synergistic combination of CDK4/6 and PI3K inhibitors that shows strong anti-Ewing sarcoma activity and improved survival in a xenograft model.

Translational Oncology · Jun 18, 2026Peer-reviewedCancer Biology